Brind.
  1. A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

Stereotaxis received FDA clearance for commercial launch and submitted applications regarding its procedures in the U.S. market.

2 reports, 2 independent Updated Sep 3
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
3
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Stereotaxis received FDA clearance for commercial launch and submitted applications regarding its procedures in the U.S. market.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Stereotaxis received FDA clearance for a diagnostic catheter and utilizes Genesis robotic navigation systems.Sub-event
  2. Stereotaxis CEO David Fischel is scheduled to present at conferences in New York City.Sub-event
  3. Stereotaxis achieved FDA clearance for commercial procedures in the U.S.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • ZacksSTXS Launches First U.S. Robotic HD Mapping With MAGiC Sweep Stereotaxis STXS, a global leader in surgical robotics for minimally invasive endovascular intervention, recently announced the successful
  • GlobeNewswireFirst US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader